Preston Klassen
Präsident bei REGULUS THERAPEUTICS INC.
Vermögen: 106 650 $ am 31.12.2024
Profil
Preston S.
Klassen is currently the President, Director & Head-Research & Development at Regulus Therapeutics, Inc. Prior to his current position, he served as the President, Chief Executive Officer & Director at Metacrine, Inc. from 2020 to 2023.
He also held the role of Executive Director-Medical at Amgen, Inc. from 2002 to 2009.
Additionally, he served as an Independent Director at Conatus Pharmaceuticals, Inc. from 2014 to 2020.
Dr. Klassen has also held director positions at Corvidia Therapeutics, Inc., Equillium, Inc., and Chinook Therapeutics, Inc. From 2017 to 2020, he served as the Chief Medical Officer, Executive VP, and Head-R&D at Arena Pharmaceuticals, Inc. Prior to that, he was the Executive VP & Head-Global Development at Orexigen Therapeutics, Inc. from 2009 to 2016.
He also served as the President & Chief Medical Officer at Sanifit Therapeutics SA from 2016 to 2017.
Dr. Klassen's education includes a graduate degree from Duke University in 2000, an undergraduate degree from Central College, and a doctorate degree from the University of Nebraska Medical Center.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
09.01.2025 | 67 500 ( 0,10% ) | 106 650 $ | 31.12.2024 | |
ZURA BIO LIMITED CLASS A
-.--% | 03.09.2024 | 0 ( -.--% ) | - $ | 31.12.2024 |
Aktuelle Nachrichten zu Preston Klassen
Aktive Positionen von Preston Klassen
Unternehmen | Position | Beginn |
---|---|---|
REGULUS THERAPEUTICS INC. | Präsident | 22.06.2023 |
Ehemalige bekannte Positionen von Preston Klassen
Unternehmen | Position | Ende |
---|---|---|
ZURA BIO LIMITED | Präsident | 11.04.2023 |
METACRINE, INC. | Vorstandsvorsitzender | 01.02.2023 |
ARENA PHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | 09.06.2020 |
HISTOGEN INC. | Direktor/Vorstandsmitglied | 01.05.2020 |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Präsident | 01.03.2017 |
Ausbildung von Preston Klassen
University of Nebraska Medical Center | Doctorate Degree |
Duke University | Graduate Degree |
Central College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
AMGEN INC. | Health Technology |
EQUILLIUM, INC. | Health Technology |
ZURA BIO LIMITED | Health Technology |
REGULUS THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Conatus Pharmaceuticals, Inc.
Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
Sanifit, Inc.
Sanifit, Inc. Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., Sanifit, Inc. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in San Diego, CA. | Health Technology |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Health Technology |
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Chinook Therapeutics, Inc. /Old/
Chinook Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Chinook Therapeutics, Inc operates as a biotechnology company, which engages in the development of medicines for kidney diseases. The company is headquartered in Vancouver, Canada. | Commercial Services |
Metacrine, Inc.
Metacrine, Inc. BiotechnologyHealth Technology Metacrine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapies for patients with liver and gastrointestinal (GI) diseases. It offers farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA. | Health Technology |